Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00911183 | Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial(FRAIL-06) | completed | Phase 2 | 67 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03695471 | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | completed | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT02998476 | A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) | completed | Phase 2 | 60 | Incyte CorporationINDUSTRY | 11 | Aug 22, 2025 | clinicaltrials |
| NCT06149247 | HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL | completed | Phase 2 | 10 | SoligenixINDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT01660607 | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | completed | Phase 1 / Phase 2 | 68 | Stanford UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT01771107 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 41 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT02916771 | Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03834688 | Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age(PrE0405) | completed | Phase 2 | 33 | PrECOG, LLC.OTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03739619 | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 3 | Emory UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03331341 | Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07102706 | Phase I Trial of GR1803 Injection in Patients With RRMM | completed | Phase 1 / Phase 2 | 76 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02278796 | A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)(BEB) | completed | Phase 2 | 108 | Insel Gruppe AG, University Hospital BernOTHER | 2 | Aug 1, 2025 | clinicaltrials |
| NCT03496779 | Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine | completed | Phase 2 | 71 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 30, 2025 | clinicaltrials |
| NCT03548207 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma(CARTITUDE-1) | completed | Phase 1 / Phase 2 | 126 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT01864018 | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | completed | Phase 1 / Phase 2 | 87 | Mayo ClinicOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT00878254 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | 25 | University of MiamiOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT03144674 | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | completed | Phase 2 | 110 | Incyte CorporationINDUSTRY | 12 | Jul 11, 2025 | clinicaltrials |
| NCT02329080 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | completed | Phase 2 | 79 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jul 8, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06511869 | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | completed | Phase 2 | 48 | Dizal PharmaceuticalsINDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03133221 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | completed | Phase 2 | 17 | University of Maryland, BaltimoreOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT02765854 | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | completed | Phase 2 | 70 | Emory UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT01995669 | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03713294 | Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma | completed | Phase 2 | 37 | Mayo ClinicOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 348 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2025 | clinicaltrials |
| NCT02750670 | Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT00001379 | Treatment and Natural History Study of Lymphomatoid Granulomatosis | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2025 | clinicaltrials |
| NCT01359592 | S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 159 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 17, 2025 | clinicaltrials |
| NCT02871219 | Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT00112827 | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | City of Hope Medical CenterOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05008224 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)(KEYNOTE-C11) | completed | Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Jun 6, 2025 | clinicaltrials |
| NCT03012880 | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03490344 | Short Course Daratumumab in Patients With Multiple Myeloma | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04062448 | A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) | completed | Phase 2 | 16 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT03113422 | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy(PrE0403) | completed | Phase 2 | 56 | PrECOG, LLC.OTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03361748 | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma(KarMMa) | completed | Phase 2 | 149 | CelgeneINDUSTRY | 8 | May 23, 2025 | clinicaltrials |
| NCT01350245 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | completed | Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04176380 | RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma | completed | Phase 2 | 15 | Rapa Therapeutics LLCINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT02580539 | A Study of the Safety and Efficacy of EBV Specific T-cell Lines(EBV-TCL-01) | completed | Phase 1 / Phase 2 | 12 | Dr. Jean-Sebastien Delisle, MD, PhDOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03583424 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT00179673 | Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 43 | CelgeneINDUSTRY | 2 | May 13, 2025 | clinicaltrials |
| NCT04402138 | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | completed | Phase 2 | 15 | SCRI Development Innovations, LLCOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT01729091 | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT03417284 | Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT00135200 | Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma | completed | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01458366 | Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide | completed | Phase 1 / Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 29, 2025source: clinicaltrials